Business Plan v4.0

BovRes BR-1 / HerdLink · Burmain Holdings (Pty) Ltd · September 2026

BovRes BR-1 / HerdLink

Early detection and outbreak surveillance for South African livestock

Business Plan v4.0

Burmain Holdings (Pty) Ltd | September 2026

Contact: Baden Dennis | bd@burmain.com | +27 71 671 5621

1. Executive Summary

South Africa is living through the worst foot-and-mouth disease (FMD) crisis in its recorded history. FMD was declared a national disaster in February 2026, cases were confirmed in all nine provinces, more than 24,000 cases were logged in 2025 alone, and the Bureau for Food and Agricultural Policy (BFAP) estimates beef export losses could reach R2.6 billion by end-2026 with a further R3.2–11.3 billion at risk to 2030. Dairy losses passed R1 billion by January 2026, at roughly R5,000 per affected cow.

The national response is vaccination: 14 million cattle targeted by December 2026, local vaccine production restarted at Onderstepoort, and a private-vaccination authorisation system launched in July 2026. Vaccination is working (new outbreaks in Gauteng fell 96% between Q4 2025 and Q3 2026), but it creates the next problem. Under WOAH rules, South Africa can only recover export status by proving, through continuous clinical and serological surveillance, that virus is no longer circulating in vaccinated herds. Vaccinated animals can still be infected, can shed virus before showing signs, and are harder to spot. The country now needs to watch 14 million vaccinated cattle for the next 12–24 months, with a veterinary service that was already overstretched before the outbreak.

BovRes BR-1 is a low-cost, self-powered, off-grid livestock collar that continuously measures body temperature, activity, rumination and lying behaviour, and flags individual animals and herds whose pattern indicates early infection, before a farmer or vet would see it. Published challenge studies show FMD-infected cattle develop fever and begin shedding virus 24–72 hours before vesicles appear, and can transmit infection at least 24 hours before clinical signs. Sensor studies in cattle show sustained temperature rises 12–136 hours before respiratory disease is clinically visible. That window is the product: catch the first animal early, isolate it, and stop a farm outbreak becoming a district outbreak.

Unlike imported ear-tag and bolus systems that sell individual-cow productivity to well-connected dairies, BR-1 is built for the South African outbreak problem: a LoRaWAN mesh that works without cellular coverage across large extensive farms, solar/kinetic power with no battery replacement, a price point (R2,499 hardware, R25/month) that a commercial beef or dairy producer can justify against R5,000-per-cow outbreak losses, herd-level and district-level outbreak analytics designed for provincial veterinary services, and a data model aligned to LITS-SA, the national traceability system now being rolled out.

What we are raising

R3.5 million seed equity, alongside a parallel application to the TIA Seed Fund and Technology Development Fund for non-dilutive support. The seed round funds three things: an independent 12-week validation study on 100 animals with a South African veterinary faculty; a 300-unit pre-production run with ICASA/SABS certification; and the three technical hires needed to take the system from prototype to field product. Target exit from seed: validated detection performance, two signed commercial pilots, and a Series A of R15–20 million in H2 2027 for scale manufacturing.

Financial summary (ZAR thousands, conservative case)

20262027202820292030
Units sold1002 0008 00022 00045 000
Active units (cumulative)1002 10010 10032 10077 100
Revenue1465 38022 03061 880130 005
Gross margin10%63%69%73%75%
EBITDA(2 885)(3 812)66218 93254 903

Break-even in 2028 at approximately 10,000 active units, under 0.1% of the national herd. Full model in Section 9.

2. The Problem

2.1 The 2025–26 FMD crisis

2.2 Why vaccination does not close the gap

Government is vaccinating 80% of the national herd (about 14 million cattle) by December 2026 and has restarted local vaccine production at ARC-Onderstepoort. This is the correct response and it is working: Gauteng recorded a 96% drop in new outbreaks between October 2025–January 2026 and June–August 2026; North West has vaccinated over 1.3 million animals. But it changes the shape of the problem rather than ending it:

2.3 The biological window

Recent peer-reviewed work has quantified the pre-clinical phase of FMD in cattle. In controlled challenge studies, nasal shedding of FMD virus was detectable from 24 hours post-exposure, virus in blood from 72 hours, and the first clinical sign (fever above 40 °C or an oral vesicle) appeared at about 96 hours. Cattle transmitted infection to naive contacts at least 24 hours before their own clinical signs. Incubation in cattle runs 2–7 days experimentally and longer in the field. Fever is consistently the earliest sign, appearing before lesions; infrared thermography studies have confirmed fever as an effective screening signal for FMD in cattle.

The implication: an animal is infectious for one to several days before anyone can see that it is sick. A device that detects the physiological onset of fever and the accompanying drop in activity, feeding and rumination, and alerts the farm the same day, converts a whole-herd exposure into a single-animal isolation event. This is well-established for bovine respiratory disease (BRD), where reticulorumen temperature boluses detect hyperthermia 12–136 hours before clinical signs and behaviour sensors detect changes up to 5–7 days earlier. BR-1 applies the same validated approach to the FMD surveillance problem, at South African scale and price.

3. The Solution: BovRes BR-1 and HerdLink

3.1 What it does

BR-1 is a ruggedised neck collar for cattle (with ear-tag and small-stock variants on the roadmap) that measures, every few minutes, without any farm infrastructure other than a solar gateway:

SignalSensorWhat it tells usSurface / core temperature proxyContact IR thermopile (MLX90614 class) at neck with ambient compensation; optional tympanic ear-tag sensorOnset of fever, the earliest FMD signActivity and lying time3-axis accelerometerLethargy, lameness onset, reluctance to standRumination and feeding proxyAccelerometer signature classification (jaw/neck motion)Drop in intake precedes visible illness by daysLocation and movementLoRaWAN RSSI trilateration; optional GPS moduleGeofence compliance, contact networks, LITS-SA movement recordsHerd contextMesh network of collars + gatewayClustering of anomalies across animals = outbreak signature

Data flows over LoRaWAN (868 MHz, ICASA licence-exempt band) from collar to collar to a solar-powered farm gateway, and from there to the HerdLink cloud over cellular or satellite backhaul. Where there is no backhaul, the gateway stores and forwards. Every animal has its own learned baseline; alerts are raised on deviation from the animal's own normal, not fixed thresholds, which is what makes the approach robust to breed, season and management differences.

3.2 Three products in one system

For the farmer: HerdLink Farm

For the vet and the state: HerdLink Surveillance

For the value chain: HerdLink Assurance

3.3 Hardware

3.4 Software and analytics

3.5 What we are not claiming

BR-1 does not treat, prevent or cure any disease. It does not replace vaccination, veterinary diagnosis or laboratory confirmation. It is a monitoring and decision-support tool, regulated as an electronic device (ICASA type approval for the radio, SABS/IEC safety), not as a veterinary medicine. Any performance figure we publish will come from independent, pre-registered studies.

4. Market

4.1 Sizing

4.2 Customer segments and who pays

SegmentPainBuyer / channelPriorityCommercial feedlots (Karan Beef, Sparta, Beefcor, Chalmar and c. 70 others)BRD losses every day; FMD lockdown risk; animals confined, high value, short cycleDirect sales; feedlot vetBeachhead: proven BRD economics, fast decision, dense deploymentCommercial dairies (KZN Midlands, Eastern Cape, Western Cape)R5,000/cow outbreak loss; milk movement restrictions; mastitis and fertilityDirect; processors (Woodlands/Fairfield, Clover, Parmalat) as channelBeachhead 2: pilot partner in Midlands under discussionExtensive commercial beefMovement bans, auction closures, lost export accessRPO, co-ops, agri retailers (Afgri, Senwes, NWK), insurers2027–28 with GPS variantProvincial veterinary services / DALRRDCannot inspect 14 million vaccinated animals; must prove freedom to WOAHB2G contracts; TIA/DALRRD innovation budgets; DFI-funded programmesSurveillance licence from 2027Communal and emerging farmersHighest disease burden, lowest ability to payGovernment and donor programmes (Land Bank blended finance, CASP, GALVmed-type funders)Subsidised deployments 2028+Exporters, processors, insurersNeed proof of monitored, alert-free supplyAssurance data licence2028+

The design principle is that the individual farmer is never the only payer. Feedlots and dairies buy on productivity economics that exist regardless of FMD; government and the value chain buy surveillance and assurance. This answers directly the objection raised by South African reviewers of our previous plan that farmers "have no cash to spend on this".

4.3 Unit economics for the customer

5. Competition and Differentiation

ProductFormStrengthsGaps for the SA outbreak problemSenseHub (Allflex / MSD Animal Health)Ear tag + neck collar; dairy, beef, feedlotMarket leader; proven early sickness detection in feedlots; SA distributionImported, priced for premium dairies; needs base-station infrastructure; no herd/district outbreak analytics; no traceability integrationsmaXtecRumen bolusBest-in-class core temperature; ruminationBolus cost and administration; cellular dependence; dairy focus; no SA manufacturingCeres TagSatellite ear tagWorks anywhere; theft and locationHigh unit price; location-first, limited health sensingMoovement, MooField, Cowlar, Nedap, CowManagerEar tags / collarsAffordable GPS and activityLocation or productivity focus; no fever detection; no outbreak surveillance layerVisual inspection + LITS-SAStatus quoFree; legally requiredDetects disease days late; does not scale to 14 million animals

5.1 Our differentiation

  1. Outbreak-first design. Every competitor sells per-cow productivity. BR-1 is designed from the ground up for herd-level and district-level early warning, contact tracing and surveillance evidence, which is what South Africa needs for the next two years.

  2. Off-grid mesh. Collar-to-collar LoRaWAN relay and a solar gateway mean no cellular coverage requirement and no per-animal SIM cost. This is decisive on extensive farms in the Karoo, Limpopo and the Eastern Cape.

  3. Price and local manufacture. Locally moulded and assembled hardware at R2,499 with R25/month software is roughly one-third to one-half the landed cost of imported systems and qualifies for local-content, TIA and IDC support.

  4. Policy alignment. Data model built to the LITS-SA identifier standard; surveillance outputs designed with WOAH Chapter 8.8 evidence requirements in mind; South African data residency.

  5. Protectable IP. Provisional patent filed (SA, Global IP Co, ref. PT/PV/ZA00002396). The complete specification will be refocused on the self-powered mesh collar architecture, the on-device baseline/anomaly method and the herd-level outbreak inference method.

6. Validation and Regulatory Plan

Credibility with investors, government and farmers depends on independent evidence. The seed round funds a staged validation programme, run with a South African veterinary faculty (target partners: University of Pretoria Faculty of Veterinary Science at Onderstepoort, or the University of KwaZulu-Natal, with ARC-Onderstepoort Veterinary Research as laboratory partner).

StageWhenDesignPass criteria0. Bench and durabilityQ4 202630 collars; sensor accuracy vs reference thermometry; IP68, UV, abrasion; power budget over 60 daysTemperature error ≤0.3 °C after compensation; zero battery-out events1. Field baseline studyQ1 2027100 animals (50 dairy at Midlands partner, 50 feedlot) for 12 weeks; blinded comparison of collar alerts against daily veterinary clinical scoring and routine treatment recordsSensitivity ≥80%, specificity ≥90% for clinical illness (BRD/mastitis/lameness); median lead time ≥24 h ahead of visual detection2. FMD-specific evaluationQ2–Q3 2027Deployment on farms under active FMD restriction in KZN/EC with provincial vet cooperation; retrospective and prospective comparison against confirmed casesDetection ahead of clinical reporting in ≥70% of confirmed cases; published protocol and results3. Surveillance pilotQ4 20272,000+ animals across one district; HerdLink Surveillance dashboard used by provincial vetsSigned B2G surveillance contract; peer-reviewed publication submitted

6.1 Regulatory

7. Go-to-Market

7.1 Sequence

  1. 2026–27: prove it. Validation study with a named dairy partner in the KZN Midlands and one feedlot. Convert both to paying reference customers.

  2. 2027: feedlots and dairies. Direct sales to the c. 70 SA feedlots and top 300 dairies, led by feedlot and dairy veterinarians as channel partners. Processor-backed roll-outs (Woodlands/Fairfield, Clover) where the processor co-funds collars in exchange for assurance data.

  3. 2027–28: state surveillance. HerdLink Surveillance licence with one province (KZN, as the declared ground-zero province with R400 million redirected to FMD control), then DALRRD nationally; DFI and donor co-funding for communal-area deployment.

  4. 2028+: extensive beef, SADC, licensing. GPS variant through agri retailers and the RPO; distribution partnerships in Botswana, Namibia and Zimbabwe; technology licensing to animal-health majors for markets we will not serve directly.

7.2 Channels and partners to secure in seed phase

7.3 Pricing

8. Team and Organisation

Burmain Holdings (Pty) Ltd is 100% founder-owned with all IP held at entity level. Founder: Baden Dennis (product, AI/automation and nanomaterials applications). [Insert founder biographies, prior ventures and relevant track record here; investors will weight this section heavily.]

Seed-funded hires

Advisory board to be formed

Hiring roadmap: 3 technical staff in 2026–27, scaling to 12–15 by end-2028 as manufacturing and field support grow.

9. Financial Plan

9.1 Assumptions

9.2 Five-year projection (ZAR thousands)

20262027202820292030
Units sold1002 0008 00022 00045 000
Active units (year end)1002 10010 10032 10077 100
Hardware revenue1254 99819 99254 978112 455
Subscription revenue153301 8306 33016 380
Gateway revenue6522085721 170
Total revenue1465 38022 03061 880130 005
Cost of sales1311 9926 86816 94833 102
Gross profit153 38815 16244 93296 903
Gross margin10%63%69%73%75%
Operating expenses2 9007 20014 50026 00042 000
EBITDA(2 885)(3 812)66218 93254 903

Cumulative EBITDA loss through 2027 is approximately R6.7 million. The R3.5 million seed round plus targeted non-dilutive funding (TIA Seed Fund / TDF, R1–3 million) carries the company through validation and first commercial sales; a Series A of R15–20 million in H2 2027 funds tooling, inventory and the sales organisation for the 2028 ramp. Break-even is reached in 2028.

9.3 Use of seed funds (R3.5 million)

ItemZARNoteValidation programme (faculty agreement, ethics, 100-animal field study, lab confirmation, publication)900,000Stages 0–2, Section 6Pre-production run of 300 collars + 4 gateways, tooling for injection moulding750,000Includes SabiNano materials and CNC/assemblyTechnical hires (3 FTE, 12 months, partially grant-matched)1,200,000Embedded/RF, ML, full-stackICASA/SABS certification and EMC/safety testing250,000Field support, travel, pilot logistics200,000KZN, EC, feedlot sitesLegal, IP (complete patent specification, PCT), audit, admin200,000Total3,500,000

9.4 Seed milestones (what the money must prove)

  1. Independent validation study complete with sensitivity, specificity and lead-time results reported by the faculty partner.

  2. 300 certified collars in the field on at least three commercial sites with paying customers.

  3. One signed provincial or DALRRD surveillance pilot agreement.

  4. Complete patent specification filed; PCT route decided.

  5. Series A term sheet.

9.5 Exit

Strategic acquisition by an animal-health major building out monitoring portfolios (MSD Animal Health/Allflex, Zoetis, Boehringer Ingelheim, Ceva, Elanco) or an agtech consolidator; or a licensing model in which Burmain retains South African and SADC operations and licenses the surveillance platform to partners in other FMD-endemic markets. Comparable transactions include Zoetis's acquisition of Performance Livestock Analytics and MSD's acquisitions of Allflex (US$2.4 billion) and Antelliq.

10. Risks and Mitigation

RiskMitigationDetection performance in the field is below targetStaged validation with kill criteria; multi-signal fusion (temperature + activity + rumination) rather than single-sensor; per-animal baselines; publish honestly and iterateFMD subsides and urgency fadesProduct economics rest on BRD, mastitis, heat and lameness detection, which exist every year; surveillance obligation persists for 12–24 months after vaccination regardless of case numbersFarmer affordabilityFeedlots/dairies as beachhead; processor and state co-funding; monthly financing via Land Bank/agri-retailersIncumbent response (MSD/Allflex price cuts)Local cost base, outbreak-surveillance layer and state relationships that incumbents lack; be acquirable rather than fightHardware durability and powerBench stage 0 before any field deployment; 5-year design life; field-replaceable strapTeam depthSeed hires and advisory board are the first use of funds; founder-market fit strengthened by veterinary co-investigatorsReputational legacy of earlier "bio-energetic" positioningFull withdrawal of prior materials; new evidence-based collateral; transparent explanation to prior contacts (see Cleanup Memo)

11. Roadmap

QuarterMilestoneQ4 2026Seed close; hires; bench/durability stage; faculty agreement and ethics; pilot LoIs executed; TIA applicationQ1 2027100-animal field study starts (dairy + feedlot); ICASA submission; complete patent specificationQ2 2027Study read-out; FMD-zone deployment with provincial vets; first commercial feedlot ordersQ3 2027300 units deployed; HerdLink Surveillance beta with province; Series A processQ4 2027Series A close; tooling for 10,000 units/yr; publication submitted20288,000 units; provincial surveillance contract; GPS variant; SADC distribution talks2029–30National scale; small-stock variant; licensing to animal-health partners; regional expansion

12. Sources

BFAP, "Initial Cost Estimates Linked to the FMD Crisis" (Feb 2026), reported by IOL, 4 Feb 2026: https://iol.co.za/business/2026-02-04-fmd-outbreaks-to-cause-significant-losses-to-south-africas-beef-dairy-industries-report/

IOL, "South Africa declares foot and mouth disease a national disaster", 15 Feb 2026: https://iol.co.za/business-report/economy/2026-02-15-south-africa-declares-foot-and-mouth-disease-a-national-disaster/

Forbes Africa, "South Africa's vaccination rollout…", 28 Feb 2026: https://www.forbesafrica.com/current-affairs/2026/02/28/south-africas-vaccination-rollout-to-control-most-devastating-foot-and-mouth-disease-outbreak-country-has-ever-seen

IOL, "KZN declared ground zero as R400m redirected…", 28 Feb 2026: https://iol.co.za/news/south-africa/2026-02-28-kzn-declared-ground-zero-as-r400m-redirected-to-fight-foot-and-mouth-outbreak/

African Farming, "Gauteng records 96% drop in new FMD outbreaks", 4 Sep 2026: https://www.africanfarming.com/2026/09/04/gauteng-records-96-drop-in-new-fmd-outbreaks/

SAnews, "North West makes progress in fight against FMD" (Aug 2026): https://www.sanews.gov.za/south-africa/north-west-makes-progress-fight-against-fmd

DALRRD, Mass Vaccination FMD Proposal, 13 Jan 2026: https://www.nda.gov.za/images/outbreaks/Foot%20and%20Mouth%20Disease%20Outbreak/vaccination-strategy_-002.pdf

PMG, Status of LITS implementation and provincial FMD update (2026): https://pmg.org.za/committee-meeting/43446/ ; LITS-SA: https://lits-sa.com/

Arzt et al., "Incubation phase transmission of foot-and-mouth disease virus in cattle: experimental evidence and simulated impacts", Scientific Reports (2025): https://www.nature.com/articles/s41598-025-34132-x

"Epidemiologic consequences of preclinical transmission of FMDV in cattle", Frontiers in Veterinary Science (2025): https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1651091/full

"The pathogenesis of foot-and-mouth disease virus: current understandings and knowledge gaps", Veterinary Research (2025): https://veterinaryresearch.biomedcentral.com/articles/10.1186/s13567-025-01545-5

Rainwater-Lovett et al., "Detection of FMDV infected cattle using infrared thermography", Vet J (2009); "Normal variation in thermal radiated temperature in cattle: implications for FMD detection", BMC Vet Res (2011): https://pmc.ncbi.nlm.nih.gov/articles/PMC3235061/

Timsit et al., "Early detection of bovine respiratory disease in young bulls using reticulo-rumen temperature boluses", Vet J (2011): https://pubmed.ncbi.nlm.nih.gov/20947394/

"Detection of physiological changes using a triaxial accelerometer and temperature sensor-equipped bolus biosensor in calves", Animals (2024): https://doi.org/10.3390/ani14192815

"Wearable collar technologies for dairy cows: a systematized review", Animals 15(3):458 (2025): https://www.mdpi.com/2076-2615/15/3/458

MarketsandMarkets, Precision Livestock Farming Market 2025–2030: https://www.marketsandmarkets.com/Market-Reports/precision-livestock-farming-market-29706557.html

WOAH Terrestrial Animal Health Code, Chapter 8.8 (FMD): https://www.woah.org/fileadmin/Home/eng/Health_standards/tahc/2024/en_chapitre_fmd.htm

Merck Animal Health, SenseHub Feedlot; Allflex South Africa: https://www.allflex.global/sa/product/sensehub-solution-for-beef/ ; smaXtec: https://www.smaxtec.com/en/

TIA funding instruments: https://www.tia.org.za/funding-instruments/ ; IDC Agro-processing and Agriculture: https://www.idc.co.za/agro-processing-agriculture/ ; Land Bank Blended Finance Scheme: https://www.gov.za/news/media-statements/minister-thoko-didiza-launches-r32-billion-blended-finance-scheme-land-bank

Confidential. Provided under NDA to prospective investors and partners of Burmain Holdings (Pty) Ltd. Not for onward distribution. This document makes no therapeutic claims; BR-1 is a monitoring and decision-support device. Performance figures will be reported from independent, pre-registered studies.